Lung cancer screening with low-dose CT is being introduced in several European countries. The management of incidental findings, both pulmonary and extrapulmonary, is an important component of the clinical and cost effectiveness of screening programs. A multi-society European group was convened to discuss the issue.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Other
November 20, 2023
April 19, 2023
This study used lung cancer screening trial low dose CT scans to develop a model (Sybil) that predicts the likelihood of development of a lung cancer within the next year. The model was then tested using images from independent data sets totaling more than 27,000 patients.
March 23, 2023
Thoracic oncology patients are a high-risk group for venous thromboembolism (VTE). The ESTS and AATS panel reviewed the evidence using the GRADE approach and made twenty-four recommendations for VTE prophylaxis, focusing on pharmacological and mechanical methods.
January 6, 2023
The FDA has approved the drug Cytalux for use in lung surgery. The drug, also known as pafolacianine, binds to lung cancer cells to make them glow under infrared light.
December 9, 2022
This study aimed to measure the population-level impact of federal lung cancer screening recommendations and Medicare coverage. After these decisions were implemented, and when adjusted for age, researchers found that they were associated with an increased incidence of early-stage lung cancer and decreased incidence of advanced-stage lung cancer.
November 4, 2022
Although equitable access to care is critical to proper surgical lung cancer management, quality measures (QMs) that assess preoperative access to care are lacking. This study determined the relationship between meeting several preoperative QMs and various short- and long-term outcomes.
February 8, 2020
The newest version of the ASCO guidelines for lung cancer surveillance after curative lung cancer therapy is presented. The overall quality of supportive evidence is low, and the strength of recommendations is moderate. CT is recommended as the optimal imaging modality.
February 1, 2020
Individuals at high risk for lung cancer were randomized to low dose CT screening (years 0, 1, 3, and 5.5) or observation. At 10 years the cumulative rate ratio for lung cancer death was 0.76 in the screened population of men (p=0.01) and 0.67 in the screened population of women, demonstrating a strong benefit for screening.
January 10, 2020
Declines in US annual lung cancer mortality rates of 5% for men and 4% for women led improvements in overall cancer mortality rates in the latest update from the American Cancer Society. This is likely linked to efforts at decreasing tobacco use, improved screening, and newer systemic therapies.
January 10, 2020
Benign-appearing lung nodules identified on screening CTs are associated with an increased risk of lung cancer diagnosis 4 to 8 and 8 to 11 years after the scan (RRs 1.9 and 1.6, respectively).